• Tarsus Pharmaceuticals’ third-quarter 2026 net loss widened year-over-year to $668.3 million.
• Net product sales rose approximately 64% year-over-year to $194.6 million, driven by higher volume and improved gross-to-net discounts.
• Acquired in-process research and development expenses totaled $632.2 million, related to the iRenix Medical and Alkeus Pharmaceuticals acquisitions.
• Topline results from Phase 2 trials of TP-04 for ocular rosacea and TP-05 for Lyme disease prevention are expected in first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031605PRIMZONEFULLFEED9869450) on November 03, 2026, and is solely responsible for the information contained therein.